Podcasts about nejm

Featuring articles on mismatch repair–deficient tumors, generalized myasthenia gravis, HER2-mutant non–small-cell lung cancer, a Corynebacterium diphtheriae outbreak, and hereditary and sporadic papillary kidney cancer; a review article on unruptured intracranial aneurysms; a case report of a man with respiratory failure and shock after kidney transplantation; and Perspectives on medical AI and clinician surveillance, on pathobiology, and on unrest.

Information on COVID vaccines is moving fast. On May 27th, HHS Secretary Robert F. Kennedy Jr. announced that COVID vaccines will no longer be universally recommended for healthy children or healthy pregnant women. That's a big shift, and understandably, it's raised a lot of questions. We're going to cut through the noise and take a look at where things really stand, who's getting vaccinated, how current guidance is evolving, and what this means for both children and adults as we look ahead to the next respiratory season.  Joining us to help sort it all out is Dr. John Schoen, Senior Clinical Manager of Drug Information at Vizient.     Guest speakers:  John Schoen, PharmD, BCPS  Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence    Host:  Stacy Lauderdale, PharmD, BCPS  Associate Vice President Vizient Center for Pharmacy Practice Excellence    Show Notes:  [01:38-05:32] What changed in the recent CDC update for healthy children [05:33-09:32] Discussion of COVID-19 outcomes and vaccination in children [09:33-11:47] Specific risk factors for pediatric patients [11:48-12:47] Is the US an outlier for not universally recommending the COVID-19 vaccine for healthy children and making no recommendation in healthy pregnant women? [12:48-14:03] The FDA's proposed regulatory framework for COVID-19 vaccine approval [14:04-15:18] FDA's approach to implementing revised requirements for randomized controlled trials [15:19-16:57] Key discussion points from the May meeting of the Vaccines and Related Biological Products Advisory Committee [17:00-18:27] Topics requiring further clarification about COVID-19 vaccine   Links | Resources: Vizient resources: Minute Market Insight: Potential ACIP COVID-19 recommendation changes April 2025: https://www.vizientinc.com/download?342668 Minute Market Insight: May 2025 COVID-19 vaccine recommendation and policy updates: https://www.vizientinc.com/download?352336 Additional resources: FDA perspective piece published in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMsb2506929 ACIP meeting information: https://www.cdc.gov/acip/meetings/index.html CDC childhood immunization schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html CDC adult immunization schedule by medical condition: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html CDC RESP-NET: https://www.cdc.gov/resp-net/dashboard/ WHO COVID-19 dashboard: https://data.who.int/dashboards/covid19/deaths MMWR - COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged

Featuring articles on treatments for pulmonary fibrosis, for obesity and overweight, for severe hemophilia B, and for a rare genetic disease; a review article on malnutrition in older adults; a case report of a man with a nasopharyngeal mass; a Medicine and Society on John Collins Warren; and Perspectives on undermining women's health research, on addressing antifungal drug resistance, and on conversations that matter in maternal medicine.

The CHALLENGE trial at ASCO 2025 showed that increased physical activity improves survival rates in colon cancer patients, with the exercise group demonstrating better health outcomes and survival rates compared to those receiving only health education. A phase 3 trial in The New England Journal of Medicine found that semaglutide significantly improves liver conditions in MASH patients, showing better resolution of steatohepatitis and fibrosis improvement compared to placebo. Additionally, a study in the NEJM revealed that combining finerenone and empagliflozin offers enhanced kidney protection in patients with chronic kidney disease and type 2 diabetes, significantly reducing urinary albumin levels.

Amanda Kallen is an associate professor in the Division of Reproductive Endocrinology and Infertility at the University of Vermont Larner College of Medicine and an adjunct professor at the Yale School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.N. Kallen and Others. Undermining Women's Health Research — Gambling with the Public's Health. N Engl J Med 2025;392:2185-2187.

Nezaměstnanost v Moravskoslezském kraji je 6 procent. Ukazují to aktuální data z úřadu práce. Za poslední měsíc tedy zůstala stejná. Největší podíl nezaměstnaných mají okresy Bruntál a Karviná. Nejméně uchazečů se hlásí na Frydecko-Místecku a Opavsku.

Původní obyvatelé amerického kontinentu trpěli leprou i kvůli jinému druhu mykobakterie, než jaký s sebou přivezli evropští kolonisté. Dokládá to výzkum, na kterém se podílely desítky evropských a amerických badatelů.Všechny díly podcastu Laboratoř můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Send us a textWhat really helps prevent injuries—and what should you do when one inevitably strikes? In this episode, I use my friend Tim's pickleball injury as a jumping-off point to explore what the evidence actually says about ice, rest, NSAIDs, stretching, and more.When Tim skipped his warm-up and pulled a calf muscle, it raised a question many of us face: was it avoidable? While ancient wisdom and modern influencers often shout conflicting advice, this episode sorts through the noise to uncover what's evidence-backed, what's outdated, and what might actually delay healing. For pain, yes, ice works—cooling slows nerve conduction and can help with comfort, as seen in this study of ankle injuries. But does it reduce inflammation in a helpful way? Possibly not. Some research suggests that vasoconstriction may hinder the delivery of reparative cells and removal of waste, as noted in this trial.The evolution from RICE to PEACE to MEAT and even PEACE & LOVE reflects our shifting understanding. A meta-analysis of 22 randomized trials found no conclusive benefit of ice when added to compression or elevation. As for NSAIDs like ibuprofen, the Cochrane Review revealed no significant advantage over acetaminophen in pain relief or swelling reduction—and no clear evidence they speed up recovery.What about rest? Surprisingly, prolonged rest may do more harm than good. The Deyo study and later NEJM data show that continued normal activity (within pain tolerance) results in faster recovery than either bed rest or structured exercises, at least for acute low back pain—offering insights that might extend to other strains or sprains.Can you prevent injuries altogether? Static stretching (think toe touches) doesn't show strong support in RCT reviews, and while a recent meta-analysis found a small reduction in muscle injuries, the impact was modest. Dynamic stretching remains inconclusive according to current evidence.The takeaway? When treatments or prevention strategies are studied over and over yet results remain ambiguous, it likely means any real benefit is small—a principle I call “Dr. Bobby's Law of Many Studies.” Compare that with fall prevention in older adults: 66 RCTs involving 47,000 people showed strength and balance training significantly reduces falls by 20–30%. When something works, it tends to show up clearly and consistently.Takeaways: If you're injured, ice and NSAIDs can ease discomfort—but don't count on them to speed up healing. Resting too much may slow recovery; try gentle movement instead. Stretching might help a bit with prevention, but don't expect miracles. Evidence

Featuring articles on metabolic dysfunction–associated steatohepatitis, lung nodules, breast cancer, and improving birth outcomes; a review article on hemoglobinopathies; a Clinical Problem-Solving on from where it stems; and Perspectives on U.S. research leadership at a crossroads, on health care in an evolving immigration landscape, and on carrying hope while facing a crisis.

In this podcast episode of Integrative Cancer Solutions Dr. Karlfeldt interviews Dr. Chris Apfel about his integrative approaches to cancer treatment. Dr. Apfel shares his journey from traditional medicine to integrative oncology, sparked by his father's lung cancer diagnosis. This personal experience led him to question conventional cancer treatments after learning about their low success rates, particularly for stage four lung cancer. Dr. Apfel discusses his development of the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments. This test evaluates a wide range of treatments including chemotherapies, targeted therapies, and repurposed drugs. He emphasizes the importance of avoiding ineffective treatments that can harm the immune system and diminish quality of life, while highlighting the potential of repurposed drugs like statins, Metformin, and Itraconazole. The conversation addresses tumor heterogeneity and the need for representative biopsy samples, particularly from metastatic sites. Dr. Apfel explains that the Onca test is commercially available, with discounts offered to patients willing to share their data for research purposes. He discusses various methods for obtaining tumor samples and the importance of timing in the collection process.Dr. Apfel emphasizes patient advocacy and the need for patients to be informed about their treatment options. He notes that the Onca test can double the odds of a positive tumor response and significantly increase median survival rates. The podcast concludes with Dr. Apfel expressing interest in collaborating with Dr. Folt's center to help more cancer patients through this innovative approach to personalized cancer treatment.About Dr Chris Apfel:Chris Apfel, MD, PhD, MBA is a physician and clinical researcher with over 100 published papers, including a six-factor clinical prediction model published in NEJM that led to the development of The Apfel Score, a clinical calculator used universally to predict the risk of postoperative nausea and vomiting, and Dr Apfel's ultimate recruitment to the US and the University of California, San Francisco.Dr. Apfel was driven to revolutionize the field of cancer patient treatment after losing his mother to a long battle with ovarian cancer and his father to lung cancer. Witnessing their suffering inspired him leave the clinical department at UCSF to develop more efficient ways to identify the best treatment plans for cancer patients.Dr Apfel received his MD and PhD from the University of Giessen in Germany and his MBA from Wharton at the University of Pennsylvania. He is the founder and CEO of SageMedic.Dr. Apfel developed the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments, potentially doubling the odds of positive tumor response.Personal experience with his father's lung cancer led Dr. Apfel to question conventional treatments after discovering their low success rates for advanced cancers.The Onca test evaluates chemotherapies, targeted therapies, and repurposed drugs like statins and Metformin, which have shown promising results in cancer treatment.Tumor heterogeneity makes it crucial to obtain representative biopsy samples, particularly from metastatic sites, to avoid ineffective treatments.Patient advocacy is essential in cancer treatment, as patients need to make informed decisions about tissue handling before surgery and find oncologists willing to consider alternative treatments based on test results.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Amar Kelkar is a physician at the Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.H. Kelkar. U.S. Research Leadership at a Crossroads — The Impact of Reducing NIH Indirect-Cost Coverage. N Engl J Med 2025;392:2081-2084.

Watch the NEJM In Studio video of this interview at NEJM.org. David Jones is the Ackerman Professor of the Culture of Medicine at Harvard University. Harleen Marwah, the interviewer, is an Editorial Fellow at the Journal. W. Xue and D.S. Jones. Debating Race and the Diagnosis of Anemia — How Medicine Moved Away from Race-Based Standards. N Engl J Med 2025;392:2168-2173.

In this episode, Dr. Thomas McGinn and guest expert Dr. Nezar Falluji discuss a new NEJM publication that explores the approaches for patients with symptomatic severe tricuspid regurgitation, comparing the outcomes and adverse events of transcatheter replacement to medical therapy.Guest: Dr. Nezar Falluji, Interventional CardiologistSystem Physician Vice President, CommonSpirit Health National Cardiovascular Service LineArticle discussed: https://www.nejm.org/doi/full/10.1056/NEJMoa2401918?query=WB&cid=NEJM%20Weekend%20Briefing,%20January%2011,%202025%20DM2381304_NEJM_Non_Subscriber&bid=-1550043199

We're back with another Rapid Fire Journal Club. Luke Hedrick and Dave Furfaro discuss the NAVIGATOR trial published in NEJM in 2021 evaluating tezepelumab for adults with asthma. Article and Reference We are talking today about the NAVIGATOR trial evaluating … Continue reading →

Vamos discutir o estudo GLORY-1 publicado no NEJM em maio 2025, avaliando o uso da mazdutida no tratamento da obesidade.

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald return for round 2 taking turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna, and whether or not these trials should change your practice. Part 2 covers the ALABAMA trial exploring the safety of penicillin-allergy delabelling using the penicillin allergy assessment pathway, the SOLARIO trial investigating short (≤7 days!) versus long (≥4 weeks) antibiotic courses for orthopaedic infections, the EAGLE-1 trial assessing oral gepotidacin for gonorrhoea, a randomised clinical trial (RCT) from Thailand on oral fosfomycin as carbapenem-sparing, de-escalating therapy in complicated UTIs, and a double-blind RCT from Israel comparing neutralising plasma to placebo for West Nile fever.    This episode was peer reviewed by Dr. Emanuele Rando of Hospital Universitario Virgen Macarena, Seville, Spain and is the second of this two-part series covering selected clinical trials presented at ESCMID Global 2025.  Late-breaker trialsSandoe J, et al. Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trialAngkanavisan K, et al. Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infection: A randomisedcontrolled trialCanetti M, et al. Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trialDudareva M, et al. Short or long antibiotic regimes in orthopaedics: the SOLARIO multicentre randomised controlled trialWilson, J. Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1) ReferencesIDSA. Public Comment: IDSA Guideline on Management and Treatment of Complicated Urinary Tract Infections; 19 Feb - 19 March 2025.Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999. Lancet. 2001. doi: 10.1016/S0140-6736(01)05480-0Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic. JAMA. 2020. doi: 10.1001/jama.2020.4984Dudareva M. In: The 42nd Annual Meeting of the European Bone & Joint Infection Society. Barcelona, Spain: 26-28 Sept 2024. Li HK, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA). NEJM. 2019 doi: 10.1056/NEJMoa1710926

Featuring articles on pulmonary arterial hypertension, oral semaglutide and cardiovascular outcomes, giant-cell arteritis, the loss of subsidized drug coverage and mortality, and neutralizing venom toxins; a review article on cancer of unknown primary site; a case report of a man with fever, nausea, and respiratory failure; and Perspectives on primary care and the free market, federal cuts at the VA, the GINA gap, and the meaning of goodbye.

Zirui Song is an associate professor of health care policy and medicine at Harvard Medical School and a general internist at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. Z. Song and J.M. Zhu. Primary Care — From Common Good to Free-Market Commodity. N Engl J Med 2025;392:1977-1979.

Send us a Text Message (please include your email so we can respond!)Episode 65! Though this is during ATS, this episode was pre-recorded so you will get some reactions to the conference in the coming episodes. Instead we have a short episode where we talk about risk factors for stress ulcers and transfusion threshold in upper GI bleeding!Risk factors: https://pubmed.ncbi.nlm.nih.gov/40315134/Transfusion threshold: https://pubmed.ncbi.nlm.nih.gov/23281973/Transfusion threshold (NEJM): https://www.nejm.org/doi/10.1056/NEJMoa1211801If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

This week's topics include USPSTF on screening for syphilis in pregnancy, when to take blood pressure medicines, comparing weight loss drugs, and a narrative intervention for PTSD after an ICU stay.Program notes:0:40 NEJM publication of comparison of obesity medications1:40 Tirzepatide versus semaglutide for 72 weeks2:41 Also had reduction in blood pressure3:26 Rise in congenital syphilis and screening4:26 Disparities among various groups5:26 Highest incidence in the last 30 years6:26 In 2023 210,000 cases of syphilis7:00 When to take blood pressure meds8:00 Monitored blood pressure in a subset8:40 Intervention for PTSD after ICU stay9:40 Self reported PTSD symptoms​​10:40 Must learn to deliver intervention11:40 Physician needed to spend 45 minutes per visit12:42 End

Featuring articles on multiple sclerosis, narcolepsy type 1, antiretroviral therapy in children with HIV, and porcine kidney xenotransplantation; a review article on Ph-positive acute lymphoblastic leukemia; a case report of a woman with peritonsillar swelling and bleeding; and Perspectives on the power of physicians in dangerous times, on community health centers, on AI-driven clinical documentation, and on driving Jackson.

Alice Chen is a primary care internist in Washington, DC, and former executive director of Doctors for America. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.T. Chen and V.H. Murthy. The Power of Physicians in Dangerous Times. N Engl J Med 2025;392:1873-1875.

Evropský statistický úřad vydal každoroční zprávu o životních podmínkách ve členských zemích EU. Podle výsledků jsou nejméně ohroženi chudobou nebo sociálním vyloučením právě Češi. „Byla by to dobrá zpráva, kdyby byla pravdivá,“ komentuje výsledky sociolog Daniel Prokop. „V Česku je samozřejmě extrémní chudoby málo. Ale tento ukazatel je mimořádně zkreslující.“ V audiozáznamu se dostane také na téma volební kampaně anebo jestli bytovou krizi mohou vyřešit slevy na hypotékách.Všechny díly podcastu Jak to vidí... můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Evropský statistický úřad vydal každoroční zprávu o životních podmínkách ve členských zemích EU. Podle výsledků jsou nejméně ohroženi chudobou nebo sociálním vyloučením právě Češi. „Byla by to dobrá zpráva, kdyby byla pravdivá,“ komentuje výsledky sociolog Daniel Prokop. „V Česku je samozřejmě extrémní chudoby málo. Ale tento ukazatel je mimořádně zkreslující.“ V audiozáznamu se dostane také na téma volební kampaně anebo jestli bytovou krizi mohou vyřešit slevy na hypotékách.

Co stojí za tak rychlým poklesem, jak zamával s rodičovstvím covid a proč už není potomek podmínkou k naplnění života. Hostem Leonarda Plus je vedoucí katedry demografie a geodemografie Přírodovědecké fakulty UK Jiřina Kocourková, která příčiny poklesu porodnosti akuálně řeší v rámci výzkumného projektu "Příležitosti a rizika individualizace společnosti". Moderuje Renata Kropáčková.

In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056 Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289) Speakers: Brad Rovin, MD Richard Furie, MD Jack Cush, MD

Featuring articles on high-risk smoldering multiple myeloma, M. tuberculosis infection, type 2 diabetes, uncontrolled hypertension, and lymphoma; a review article on the chemistry of food; a case report of a man with weight loss, weakness, and anorexia; and Perspectives on the dismantling of foreign-assistance efforts, on the crushing weight of nonclinical demands in primary care, and on the last dose.

Christopher Duggan is the director of the Center for Nutrition at Boston Children's Hospital, a professor of pediatrics at Harvard Medical School, and a professor in the Departments of Nutrition and Global Health and Population at the Harvard T.H. Chan School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C.P. Duggan and Z.A. Bhutta. “Putting America First” — Undermining Health for Populations at Home and Abroad. N Engl J Med 2025;392:1769-1771.

會談地圖Podcast

Featuring articles on lipoprotein(a), familial polycythemia, leukocyte adhesion deficiency, COPD, and on policies on reducing alcohol consumption; a review article on addressing alcohol use; a Clinical Problem-Solving on gazing into a crystal ball; and Perspectives on death and taxes, on cancer metastases, and on a good innings.

A JAMA model warns measles could become endemic in the U.S. within 21 years if MMR vaccination rates don't rise, with over 850,000 projected cases. A Phase 3 NEJM trial found brensocatib reduced exacerbations in non-CF bronchiectasis. An EPIC study correlated higher breast cancer risk to higher education levels, beyond lifestyle and reproductive factors.

Arthur Robin Williams is an associate professor of clinical psychiatry at Columbia University and a research scientist at the New York State Psychiatric Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.R. Williams. Death and Taxes — Is Alcohol the Solution? N Engl J Med 2025;392:1665-1667.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - NEJM 2.     Diabetes and Anemia – Diabetes Care 3.     Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials – Diabetes Care 4.     Cardiovascular and Kidney Outcomes and Mortality With Long- Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials – Diabetes Care 5.     Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - NEJM   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Featuring articles on bronchiectasis, influenza, clonal hematopoiesis of indeterminate potential, and metachromatic leukodystrophy; a review article on biology of the Fc neonatal receptor; a case report of a woman with sore throat and rash; and Perspectives on HIV preexposure prophylaxis, on fossil fuels, and on Medicaid's mandate for children and adolescents.

Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.

Send us a Text Message (please include your email so we can respond!)Episode 63! We talk about intermediate risk PE in "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism" by Jaber et al published in Circulation in February 2025. Then we talk about "Fibrinolysis for patients with intermediate-risk pulmonary embolism" by Meter et al in NEJM 2014.PEERLESS: https://pubmed.ncbi.nlm.nih.gov/39470698/PEITHO: https://pubmed.ncbi.nlm.nih.gov/24716681/PE Meta-analysis: https://pubmed.ncbi.nlm.nih.gov/24938564/If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

In this NEJM Outbreaks Update, Editor-in-Chief Eric Rubin and Deputy Editor Lindsey Baden are joined by Indiana Commissioner of Public Health Lindsay Weaver to discuss the current state of avian influenza in Indiana. Eric Rubin is the Editor-in-Chief of the Journal. Lindsey Baden is a Deputy Editor of the Journal. Lindsay Weaver is the Indiana Commissioner of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin and Others. NEJM Outbreaks Updates — H5N1 in Indiana. N Engl J Med. DOI: 10.1056/NEJMe2503583.

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I FAME 3 at Five Years Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4 Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299 Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057 II TAVR in Low-Risk Patients at 5 years 5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004 EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428 PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447 NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606 III The Matter of Pacemakers After TAVI JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028 Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals   IV Mavacamten Looks to Have Specific Indications EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050 BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/ FINAL THOUGHTS PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Featuring articles on obinutuzumab in active lupus nephritis, tecovirimat for mpox, treatments for paroxysmal atrial fibrillation, and gene therapy for hemophilia B; a review article on enteral nutrition in hospitalized adults; a case report of a woman with cough and weight loss; and Perspectives on withdrawal of the United States from the WHO, on what's next for nicotine, on the value zeitgeist, and on doctors in revolution and war.

Patricia Zettler is a professor of law at The Ohio State University Moritz College of Law. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. P.J. Zettler, T.L. Wagener, and M.L. Berman. What's Next for Nicotine? The Coming Legal and Political Battles over an FDA Proposal. N Engl J Med 2025;392:1461-1463.

Welcome to Simulcast! In this special episode, Victoria Brazil is joined by Hege Ersdal and Benjamin Kamala, the joint first authors of a ground-breaking study just published in the New England Journal of Medicine. Their program aimed to reduce birth-related mortality in Tanzania, with spectacular success. The Safer Births Bundle integrated key elements: innovative simulation training, data-driven quality improvements, advanced clinical devices, and international collaboration and local empowerment. Neonatal mortality was reduced by 40 % and maternal deaths reduced by 75%. Congratulations to all involved.  The article:  Kamala BA, Ersdal HL, Moshiro RD, Guga G, Dalen I, Kvaløy JT, Bundala FA, Makuwani A, Kapologwe NA, Mfaume RS, Mduma ER, Mdoe P; Safer Births Bundle of Care Study Group. Outcomes of a Program to Reduce Birth-Related Mortality in Tanzania. N Engl J Med. 2025 Mar 13;392(11):1100-1110. doi: 10.1056/NEJMoa2406295. 

Featuring articles on cancer-associated venous thromboembolism, endovascular treatment for stroke, dapagliflozin in patients undergoing TAVI, screening for prostate cancer, and extrachromosomal DNA; a review article on otitis media in young children; a case report of a woman with flank pain, fever, and hypoxemia; and Perspectives on some efforts toward equity and on breaking the sacred promise.

John Patrick Co is vice president of education at Mass General Brigham and an associate professor of pediatrics at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.F. Weinstein, E. Olson, and J.P.T. Co. Addressing Socioeconomic Barriers to Residency Choice. N Engl J Med 2025;392:1353-1355.

Demografická krize v Česku! Nejméně narozených dětí od založení republiky! Tak straší čtenáře novinové titulky. A politici už si připravují do kampaně recepty, kterými jistojistě „rozrodí“ české ženy.Politické strany si to často představují jednoduše - zasypeme rodiny penězi, tu zvýšíme rodičák, tu přilepšíme na daních. „Jenže takhle jednoduché to není. Lidi se rozhodují podle jiných věcí. A naopak se ukazuje, že v největších problémech jsou nejbohatší státy,“ říká ve Vlevo dole Václav Dolejší.Že ekonomické pobídky nefungují, si vyzkoušeli například v Polsku nebo v Maďarsku (kam se jezdí učit například šéf ANO Andrej Babiš). Jenže podle statistik nejsou spásná ani řešení skandinávských zemí typu částečné úvazky, otcovská či školky.„Po těchto měkkých opatřeních volají hlavně liberálnější strany. Dlouho se myslelo, jak jim to na severu skvěle funguje, ale i jim porodnost klesá,“ popisuje Lucie Stuchlíková.Zkrátka ať se politici snaží, jak se snaží, všemožná podpůrná opatření mají jen omezený efekt. A očekávat od nich zázračné zvýšení čísel by bylo naivní. „Politici k tématu přistupují vlastně hrozně cynicky - děti je zajímají jen proto, aby se nám nezhroutil důchodový systém. Když se budoucí plátce narodí, už je jedno, jestli bude mít pediatra nebo jestli najde místo na střední škole. A na matku se mračíme, když s dítětem vystrčí nos z hřiště,“ dodává Lucie Stuchlíková.A nepřemýšlíme nad tím příliš nakonec my všichni? „Byl jsem na semináři v senátu, kde přednášely skoro samé expertky. A ty říkaly, že o pořizování jako společnost příliš složitě přemýšlíme. A že bychom k tomu měli přistupovat víc intuitivně. Prostě zavři oči a roď,“ říká s nadsázkou Václav Dolejší.Chtějí mladí příliš dokonalé hnízdo, nebo alespoň nějaké hnízdo? Co je to spermagedon? A který z českých politiků vyrobil nejvíce budoucích daňových poplatníků? Dozvíte se v čerstvé epizodě Vlevo dole!----Vlevo dole řeší politické kauzy, boje o vliv i šeptandu z kuloárů Sněmovny. Vychází každou středu v poledne.Podcast pro vás připravují Lucie Stuchlíková (@StuchlikovLucie) a Václav Dolejší (@VacDol), reportéři Seznam Zpráv.Další podcasty, ale taky články, komentáře a videa najdete na zpravodajském serveru Seznam Zprávy. Poslouchejte nás na webu Seznam Zpráv, na Podcasty.cz nebo ve své oblíbené podcastové aplikaci.Své názory, návrhy, otázky, stížnosti nebo pochvaly nám můžete posílat na adresu audio@sz.cz.Sledujte @SeznamZpravy na sociálních sítích: Twitter // Facebook // Instagram.Seznam Zprávy jsou zdrojem původních informací, nezávislé investigace, originální publicistiky.

In this episode, we add another article to our Rapid Fire Journal Club. Luke Hedrick and Dave Furfaro discuss the MIST 2 trial published in NEJM in 2011 evaluating enzymatic therapy for complex parapneumonic effusions and empyemas.   Article and … Continue reading →

V posledních dnech se odehrály dva incidenty, při kterých ozbrojenci Hamásu zabili člena některého z vlivných klanů v Gaze. Nejméně v jednom případě se příbuzní mrtvého pomstili, a veřejně popravili člena Hamásu, kterého označili za pachatele.

Featuring articles on HIV prevention, left atrial appendage closure after ablation for atrial fibrillation, timing of thrombolysis for stroke, congenital diarrhea and enteropathy, and the association between wealth and mortality in the United States and Europe; a review article on malaria; a Clinical Problem-Solving describing a “hot” cardiomyopathy; and Perspectives on physician shadowing, application overload, medical school grading, and impersonal personal statements.

In this episode of PICU DOC on Call, Dr. Rahul Damania and Dr. Pradip Kamat discuss the resurgence of measles in the United States. They explore the virus's pathophysiology, clinical features, diagnostic methods, treatment options, and complications. They emphasize the critical role of vaccination in preventing measles outbreaks and address the historical context and public health challenges related to vaccine hesitancy. The speakers highlight the severe complications of measles, especially in immunocompromised patients, and advocate for robust vaccination efforts to protect vulnerable populations and prevent the spread of this preventable disease. Tune in to hear more!Show Highlights:Resurgence of measles in the United StatesHistorical context of measles outbreaks and vaccination impactCurrent statistics and recent cases of measlesPathophysiology of the measles virusClinical features and progression of measles infectionDiagnostic approaches for confirming measlesDifferential diagnosis considerations for fever and rashTreatment options and the role of vaccinationComplications associated with measles, including severe outcomesPublic health challenges related to vaccine hesitancy and advocacy for immunizationResources:CDC Measles Info PageWHO Measles Global SurveillanceReferences:Fuhrman & Zimmerman. Textbook of Pediatric Critical Care, Ch. 52Long S et al. Principles and Practice of Pediatric Infectious Diseases, Ch. 227Moss WJ. Measles. Lancet. 2017;390(10111):2490-2502Paules CI, Marston HD, Fauci AS. NEJM. 2019;380(23):2185-2187

Featuring articles on intensive blood-pressure control in patients with diabetes, IgG4-related disease, severe chronic rhinosinusitis, advanced breast cancer, and vaccinating against C. difficile infection; a review article on chronic cough in adults; a case report of a man with hepatocellular carcinoma; an editorial on order out of chaos; and Perspectives on health care bridges, on partnerships between pharmaceutical and telehealth companies, and on the definition of failure.